[Towards a molecular classification of gliomas].
Several molecular genetic alterations have been characterized in gliomas in the past years. Molecular profiles have been associated with specific histologic and prognostic tumor subgroups, contributing to improve the classification of gliomas. At least two alternative molecular pathways have been suggested in the astrocytoma progression involving TP53 inactivation (secondary glioblastomas) and EGFR amplification (de novo glioblastomas) respectively. Oligodendroglial tumors have demonstrated recurrent combined loss of chromosome 1p/19q, which represent a favorable prognosis marker and probably a predictor of a good chemosensitivity of the tumor. This review discusses recent molecular advances and clinical implications with special focus on oligodendroglial tumors.
Hoang-Xuan
Khê
K
Service de neurologie Mazarin, Laboratoire de neuropathologie R. Escourolle, Inserm U495, CHU Pitié-Salpêtrière, 47 bd de l'Hôpital, 75651 Paris Cedex 13. khe.hoang-xuan@psl.ap-hop-paris.fr
Idbaih
Ahmed
A
Mokhtari
Karima
K
Sanson
Marc
M
D001254:Astrocytoma / Q000235:genetics / Q000473:pathology; D001932:Brain Neoplasms / Q000145:classification / Q000235:genetics* / Q000473:pathology; D002869:Chromosome Aberrations; D002872:Chromosome Deletion; D002878:Chromosomes, Human, Pair 1; D018773:Genes, erbB-1 / Q000235:genetics; D016158:Genes, p53 / Q000235:genetics; D005910:Glioma / Q000145:classification / Q000235:genetics* / Q000473:pathology; D006801:Humans; D009837:Oligodendroglioma / Q000235:genetics / Q000473:pathology; D011379:Prognosis